StockData
AbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL) income statement

ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30172% above fair value
$11.02−0.01 (-0.09%)

Close on Nov 18, 2026Market cap $3.38BP/E –Yield –

AbCellera Biologics Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-340.3%
Net margin
-248.8%
Return on equity, FY2025
-14.5%

Financial strength

Current ratio
12.77
Debt to equity
–
Debt to assets
–
Cash to current liabilities
225.7%

Valuation

P/E ratio
–
Price to sales
51.06
Price to book
3.77
Dividend yield
–

See a number that looks wrong?